Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
124M
-
Number of holders
-
353
-
Total 13F shares, excl. options
-
125M
-
Shares change
-
+1.13M
-
Total reported value, excl. options
-
$5.51B
-
Value change
-
+$52.9M
-
Put/Call ratio
-
0.34
-
Number of buys
-
199
-
Number of sells
-
-128
-
Price
-
$44.00
Significant Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q2 2022
386 filings reported holding HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q2 2022.
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) has 353 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 125M shares
.
Largest 10 shareholders include BlackRock Inc. (18.4M shares), VANGUARD GROUP INC (13.3M shares), Artisan Partners Limited Partnership (6.37M shares), STATE STREET CORP (5.92M shares), Invesco Ltd. (5.57M shares), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (4.57M shares), SNYDER CAPITAL MANAGEMENT L P (4.11M shares), JPMORGAN CHASE & CO (4.09M shares), MACQUARIE GROUP LTD (2.52M shares), and GEODE CAPITAL MANAGEMENT, LLC (2.44M shares).
This table shows the top 353 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.